Cambridge Diagnostic Innovation Set For Global Impact On Lung Cancer Screening
February 15,2019 ( PR Submission Site ) Rapid Biosensor Systems (RBS), the technology company that developed a 2-minute breathalyser test for TB, can adapt its platform technology for screening of lung cancer.
As per recent WHO statistics, Cancer has been identified as the second most predominant reason for mortality cases across the globe, accounting for and is responsible for an estimated 9.6 million deaths in 2018. Globally, more than 16 per cent of death is due to cancer. High mortality rates due to cancer can be attributed to a late-stage presentation and inaccessible diagnosis and treatment options. In 2017, only 26 per cent of low-income countries were reported to have pathology services available to the general public. More than 90 per cent of high-income countries reported the availability of treatment services whereas only 30 per cent of low-income countries have adequate treatment services.
Between 30–50 per cent of cancers can currently be prevented by early diagnosis. Early detection of lung cancer could save 10,000 lives and £300 million in the U.K. alone. The need for early diagnosis is consistent in all settings and for all categories of cancers. In the absence of an early diagnosis, patients are diagnosed at late stages when curative treatment may no longer be an option. Early detection of cancer can enhance the chances of receiving prompt treatment – a potential benefit extended by the RBS breath technology.
Designed for point-of-care diagnostic needs, RBS bio-optical disposable breathalyser device is expected to detect the presence of protein biomarkers associated with lung cancer – instantly, reliably and cost-effectively with minimal disruption. Largely due to the convenience and portability it affords, RBS breathalyser will become an essential tool to facilitate early cancer diagnosis.
Dennis Camilleri, Chief Executive Officer of RBS is confident that a higher degree of specificity and sensitivity over current screening methods along with rapid test results will create significant interest among stakeholder groups in cancer care. We could start seeing commercially – viable breath tests for screening of lung cancer in the next 2 to 3 years.
About Rapid Biosensor Systems
RBS is a Cambridge-based technology and business development company exploiting technology for rapid screening of infectious diseases. Our first product is a breathalyser-style device for screening TB in a few minutes at the point of care.
The RBS TB Breathalyser is small, robust and simple to use. It is non-invasive and cost-effective in operation. The company’s patent-protected technologies are based on existing and proven componentry which is scale-able in production volume.